Literature DB >> 26726746

Inhalation Properties and Stability of Nebulized Naked siRNA Solution for Pulmonary Therapy.

Kohei Tahara, Wakana Hashimoto, Hirofumi Takeuchi.   

Abstract

The use of naked unmodified small interfering RNA (N-siRNA) without vector has previously been investigated as a pulmonary therapy. However, little is known regarding stabilities and aerodynamic particle sizes of N-siRNA-containing droplets; nebulizers have not yet been optimized for N-siRNA solutions. Thus, in this study, we investigated the feasibility of inhaled N-siRNA solutions for pulmonary therapy using nebulization. Various nebulizers and N-siRNA concentrations were assessed in terms of siRNA integrity after nebulization, and inhalation properties including aerodynamic particle size were examined. In comparison with ultrasonic-, air-jet-, and vibrating-mesh nebulizers, N-siRNA integrity was not affected by nebulization. Thus, in further experiments, performances of N-siRNA aerosols with different nebulizers and N-siRNA concentrations were evaluated and screened using an aerodynamic particle sizer (APS) which employed the time-of-flight principle or a cascade impactor. Mean mass aerodynamic diameters of N-siRNA-containing droplets from vibrating-mesh nebulizers tended to decrease with increasing N-siRNA concentrations, reflecting the influence of N-siRNA solutions on surface tension, as indicated by contact angles. These data indicate the utility of APS instruments for investigating the nebulized characteristics of expensive drugs including siRNAs and may facilitate the development of N-siRNA inhalation formulations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26726746     DOI: 10.1248/cpb.c15-00615

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  3 in total

Review 1.  Oligonucleotide therapeutics in neurodegenerative diseases.

Authors:  Daniel R Scoles; Stefan M Pulst
Journal:  RNA Biol       Date:  2018-06-01       Impact factor: 4.652

Review 2.  siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?

Authors:  Aditi Mehta; Thomas Michler; Olivia M Merkel
Journal:  Adv Healthc Mater       Date:  2021-01-27       Impact factor: 11.092

3.  Dry Powder Inhalers for Proteins Using Cryo-Milled Electrospun Polyvinyl Alcohol Nanofiber Mats.

Authors:  Takaaki Ito; Eriko Yamazoe; Kohei Tahara
Journal:  Molecules       Date:  2022-08-12       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.